Home The Word Brain	My Amedeo FAQ Privacy About
	C49 + CC Journal Club For more information, please refer to our special emails from April 13 and May 19.

Hypertension

Free Subscription Articles published in Eur J Pharmacol Retrieve available abstracts of 55 articles: HTML format

Single Articles

May 2025
1. WANG Y, Zhang Y, An X, Jiang Y, et al
   New LFA-1 inhibitor Orientin reduces angiotensin II-induced vascular remodeling.
   Eur J Pharmacol. 2025;995:177426.
   PubMed     Abstract available
   
   
   
2. MINARI TP, Pisani LP
   Exploring Sodium Nitrate Supplementation in Enhancing Nitric Oxide Bioavailability and Reducing Oxidative Stress: Implications for Blood Pressure and Endothelial Dysfunction in Hypertension.
   Eur J Pharmacol. 2025 May 3:177702. doi: 10.1016/j.ejphar.2025.177702.
   PubMed     Abstract available
   
   
   April 2025
3. WANG H, Peng LJ, Lu W, Li GR, et al
   Acacetin reverses hypoxic pulmonary hypertension by inhibiting hypoxia-induced proliferation of pulmonary artery smooth muscle cells via SIRT1-HMGB1 pathway.
   Eur J Pharmacol. 2025 Apr 19:177650. doi: 10.1016/j.ejphar.2025.177650.
   PubMed     Abstract available
   
   
   March 2025
4. BISWAS AM, Emran T, Khan SI, Shabnam S, et al
   Transforming Growth Factor-beta-mediated attenuation of cardio-renal oxidative stress, inflammation and fibrosis by L-arginine in fludrocortisone acetate induced-hypertensive rats.
   Eur J Pharmacol. 2025 Mar 26:177559. doi: 10.1016/j.ejphar.2025.177559.
   PubMed     Abstract available
   
   
   
5. CARVALHO KFS, de Lima JF, Silva JLM, de Almeida CR, et al
   Toll-like receptor 9 contributes to perivascular adipose tissue dysfunction in spontaneously hypertensive rats.
   Eur J Pharmacol. 2025;998:177524.
   PubMed     Abstract available
   
   
   February 2025
6. HAMDY A, El-Bassossy HM, Elshazly SM, El-Sayed SS, et al
   Statins boost beneficial pleiotropic cardiovascular effects of cilostazol in angiotensin-II hypertensive rats.
   Eur J Pharmacol. 2025 Feb 27:177442. doi: 10.1016/j.ejphar.2025.177442.
   PubMed     Abstract available
   
   
   
7. SHANAHATI D, Yang T, Fang L, Nijiati Y, et al
   18beta-Glycyrrhetinic acid improves pulmonary hypertension by regulating the vascukar non-inflammatory molecule-1/L-arginine/nitric oxide signaling pathway.
   Eur J Pharmacol. 2025 Feb 21:177382. doi: 10.1016/j.ejphar.2025.177382.
   PubMed     Abstract available
   
   
   
8. GUO Z, Wu M, Chen L, Chen H, et al
   Neferine attenuates hypertensive cardiomyocyte apoptosis and modulates key signaling pathways: An in vivo and in vitro study.
   Eur J Pharmacol. 2025;994:177393.
   PubMed     Abstract available
   
   
   
9. BAI J, Gao D, Mei J, Yuan H, et al
   Exonic CircGUCY1A2 Inhibits Pulmonary Artery Smooth Muscle Cells Phenotypic Switching Via Regulating O-glycosylation of COL3A1 in Pulmonary Hypertension.
   Eur J Pharmacol. 2025 Feb 4:177328. doi: 10.1016/j.ejphar.2025.177328.
   PubMed     Abstract available
   
   
   January 2025
10. JOVANOVIC A
    Editorial: Research and development of new treatments for hypertension.
    Eur J Pharmacol. 2025 Jan 31:177321. doi: 10.1016/j.ejphar.2025.177321.
    PubMed    
    
    
    
11. JOVANOVIC A
    Editorial: Research and development of new treatments for hypertension.
    Eur J Pharmacol. 2025 Jan 28:177318. doi: 10.1016/j.ejphar.2025.177318.
    PubMed    
    
    
    December 2024
12. SHARMA A, Kapur S, Kancharla P, Yang T, et al
    Sex differences in gut microbiota, hypertension, and cardiovascular risk.
    Eur J Pharmacol. 2024;987:177183.
    PubMed     Abstract available
    
    
    
13. GAWRYS O, Kala P, Sadowski J, Melenovsky V, et al
    Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
    Eur J Pharmacol. 2024;987:177175.
    PubMed     Abstract available
    
    
    November 2024
14. LU G, Du R, Lu L, Wang Q, et al
    Macrophage-specific kappa-OR knockout exacerbates inflammation in hypoxic pulmonary hypertension.
    Eur J Pharmacol. 2024 Nov 23:177152. doi: 10.1016/j.ejphar.2024.177152.
    PubMed     Abstract available
    
    
    
15. PARVAN R, Aboumsallem JP, Meijers WC, De Boer RA, et al
    Innovative hypertension treatments: Transitioning from conventional therapies to siRNA-based solutions.
    Eur J Pharmacol. 2024;985:177110.
    PubMed     Abstract available
    
    
    
16. ZHANG F, Guo Z, Wu M, Lin G, et al
    Trifolin Attenuates Hypertension-Mediated Cardiac Injury by Inhibiting Cardiomyocyte Apoptosis: Mechanistic Insights and Therapeutic Potential.
    Eur J Pharmacol. 2024 Nov 9:177125. doi: 10.1016/j.ejphar.2024.177125.
    PubMed     Abstract available
    
    
    
17. BROSOLO G, Da Porto A, Marcante S, Capilupi F, et al
    The role for omega-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota.
    Eur J Pharmacol. 2024;985:177107.
    PubMed     Abstract available
    
    
    
18. LIU A, Wang Y, Zheng S, Bao Z, et al
    Endonuclear Circ-calm4 regulates ferroptosis via a circR-Loop of the COMP gene in pulmonary artery smooth muscle cells.
    Eur J Pharmacol. 2024;982:176944.
    PubMed     Abstract available
    
    
    October 2024
19. LIU DD, Liu XL, Zheng TF, Li X, et al
    Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels.
    Eur J Pharmacol. 2024;981:176875.
    PubMed     Abstract available
    
    
    
20. WINNER G J, Jain S, Gupta D
    Unveiling Novel Molecules and Therapeutic Targets in Hypertension - A Narrative Review.
    Eur J Pharmacol. 2024 Oct 9:177053. doi: 10.1016/j.ejphar.2024.177053.
    PubMed     Abstract available
    
    
    
21. WANG H, Gao Y, Bai J, Liu H, et al
    CircLMBR1 inhibits phenotypic transformation of hypoxia-induced pulmonary artery smooth muscle via the splicing factor PUF60.
    Eur J Pharmacol. 2024;980:176855.
    PubMed     Abstract available
    
    
    September 2024
22. R MURALITHARAN R, Marques FZ, O'Donnell JA
    Recent advancements in targeting the immune system to treat hypertension.
    Eur J Pharmacol. 2024 Sep 18:177008. doi: 10.1016/j.ejphar.2024.177008.
    PubMed     Abstract available
    
    
    
23. CASTIGLIONI L, Gelosa P, Muluhie M, Mercuriali B, et al
    Fenofibrate reduces cardiac remodeling by mitochondrial dynamics preservation in a renovascular model of cardiac hypertrophy.
    Eur J Pharmacol. 2024;978:176767.
    PubMed     Abstract available
    
    
    
24. BLASCKE DE MELLO MM, Neves VGO, Parente JM, Pernomian L, et al
    Sarcoplasmic reticulum calcium ATPase (SERCA) proteolysis by matrix metalloproteinase-2 contributes to vascular dysfunction in early hypertension.
    Eur J Pharmacol. 2024;983:176981.
    PubMed     Abstract available
    
    
    July 2024
25. WANG Y, Han D, Chai L, Qiu Y, et al
    MFN2-dependent mitochondrial dysfunction contributes to Relm-beta-induced pulmonary arterial hypertension via USP18/Twist1/miR-214 pathway.
    Eur J Pharmacol. 2024 Jul 31:176828. doi: 10.1016/j.ejphar.2024.176828.
    PubMed     Abstract available
    
    
    
26. ZHAO Z, Fan Q, Zhang C, Zheng L, et al
    Imperatorin attenuates CCl(4)-induced cirrhosis and portal hypertension by improving vascular remodeling and profibrogenic pathways.
    Eur J Pharmacol. 2024 Jul 30:176833. doi: 10.1016/j.ejphar.2024.176833.
    PubMed     Abstract available
    
    
    
27. BLAZEK O, Bakris GL
    A review of Novel Endothelin antagonists and overview of non-steroidal mineralocorticoid antagonists for treating resistant hypertension: An Update.
    Eur J Pharmacol. 2024 Jul 22:176752. doi: 10.1016/j.ejphar.2024.176752.
    PubMed     Abstract available
    
    
    June 2024
28. WANG X, Cui L, Wang Y, Zeng Z, et al
    Mechanistic investigation of wogonin in delaying the progression of endothelial mesenchymal transition by targeting the TGF-beta1 pathway in pulmonary hypertension.
    Eur J Pharmacol. 2024;978:176786.
    PubMed     Abstract available
    
    
    
29. DAI X, Liu Y, Wu Y, Wang S, et al
    DYZY01 alleviates pulmonary hypertension via inhibiting endothelial cell pyroptosis and rescuing endothelial dysfunction.
    Eur J Pharmacol. 2024;978:176785.
    PubMed     Abstract available
    
    
    May 2024
30. SHELKE V, Dagar N, Puri B, Gaikwad AB, et al
    Natriuretic peptide system in hypertension: Current understandings of its regulation, targeted therapies and future challenges.
    Eur J Pharmacol. 2024;976:176664.
    PubMed     Abstract available
    
    
    April 2024
31. YAMAMURA A, Fujiwara M, Kawade A, Amano T, et al
    Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension.
    Eur J Pharmacol. 2024;973:176564.
    PubMed     Abstract available
    
    
    
32. LAXMI, Golmei P, Srivastava S, Kumar S, et al
    Single nucleotide polymorphism-based biomarker in primary hypertension.
    Eur J Pharmacol. 2024;972:176584.
    PubMed     Abstract available
    
    
    
33. LI Q, Cao H, Xu X, Chen Y, et al
    Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A(2) receptor and hypertension via the AMPK/SIRT1 and MAPK/NF-kappaB pathways in the rat mesenteric artery.
    Eur J Pharmacol. 2024;972:176543.
    PubMed     Abstract available
    
    
    March 2024
34. BENCZE M, Boros A, Behuliak M, Vavrinova A, et al
    Changes in cardiovascular autonomic control induced by chronic inhibition of acetylcholinesterase during pyridostigmine or donepezil treatment of spontaneously hypertensive rats.
    Eur J Pharmacol. 2024 Mar 25:176526. doi: 10.1016/j.ejphar.2024.176526.
    PubMed     Abstract available
    
    
    
35. WANG J, Liu C, Huang SS, Wang HF, et al
    Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension.
    Eur J Pharmacol. 2024;970:176492.
    PubMed     Abstract available
    
    
    
36. CHEN Y, Liu J, Zhang Q, Chai L, et al
    Activation of CaMKII/HDAC4 by SDF1 contributes to pulmonary arterial hypertension via stabilization Runx2.
    Eur J Pharmacol. 2024;970:176483.
    PubMed     Abstract available
    
    
    
37. TANNA S, Doshi G, Godad A
    siRNA as potential therapeutic strategy for hypertension.
    Eur J Pharmacol. 2024;969:176467.
    PubMed     Abstract available
    
    
    February 2024
38. FU LY, Yang Y, Tian H, Jia XY, et al
    Central administration of AICAR attenuates hypertension via AMPK/Nrf2 pathway in the hypothalamic paraventricular nucleus of hypertensive rats.
    Eur J Pharmacol. 2024 Feb 8:176373. doi: 10.1016/j.ejphar.2024.176373.
    PubMed     Abstract available
    
    
    January 2024
39. LIU Q, Luo Q, Zhong B, Tang K, et al
    Salidroside attenuates myocardial remodeling in DOCA-salt-induced mice by inhibiting the endothelin 1 and PI3K/AKT/NFkappaB signaling pathways.
    Eur J Pharmacol. 2024;962:176236.
    PubMed     Abstract available
    
    
    
40. LI MH, Liu X, Xie YL, Tang XG, et al
    Sodium butyrate alleviates right ventricular hypertrophy in pulmonary arterial hypertension by inhibiting H19 and affecting the activation of let-7g-5p/IGF1 receptor/ERK.
    Eur J Pharmacol. 2024 Jan 2:176315. doi: 10.1016/j.ejphar.2024.176315.
    PubMed     Abstract available
    
    
    December 2023
41. FAN Q, Wu G, Chen M, Luo G, et al
    Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats.
    Eur J Pharmacol. 2023 Dec 27:176278. doi: 10.1016/j.ejphar.2023.176278.
    PubMed     Abstract available
    
    
    
42. QAYYUM MI, Ullah S, Rashid U, Sadiq A, et al
    N-phenyl and N-benzyl substituted succinimides: Preclinical evaluation for their antihypertensive effect and underlying mechanism.
    Eur J Pharmacol. 2023 Dec 22:176195. doi: 10.1016/j.ejphar.2023.176195.
    PubMed     Abstract available
    
    
    
43. HUANG J, Xie Y, Chen B, Xia Y, et al
    GPR146 regulates pulmonary vascular remodeling by promoting pulmonary artery smooth muscle cell proliferation through 5-lipoxygenase.
    Eur J Pharmacol. 2023;961:176123.
    PubMed     Abstract available
    
    
    
44. LI D, Chen Y, Wang Y, Liu J, et al
    NAMPT mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation by TLR4/NF-kappaB/PLK4 signaling pathway.
    Eur J Pharmacol. 2023;961:176151.
    PubMed     Abstract available
    
    
    
45. SILVA-VELASCO DL, Hong E, Beltran-Ornelas JH, Sanchez-Lopez A, et al
    Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS.
    Eur J Pharmacol. 2023 Dec 12:176266. doi: 10.1016/j.ejphar.2023.176266.
    PubMed     Abstract available
    
    
    
46. MANEESAI P, Potue P, Khamseekaew J, Sangartit W, et al
    Kaempferol protects against cardiovascular abnormalities induced by nitric oxide deficiency in rats by suppressing the TNF-alpha pathway.
    Eur J Pharmacol. 2023;960:176112.
    PubMed     Abstract available
    
    
    
47. XU Q, Zhuo K, Zhang X, Zhen Y, et al
    The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Eur J Pharmacol. 2023 Dec 5:176252. doi: 10.1016/j.ejphar.2023.176252.
    PubMed     Abstract available
    
    
    November 2023
48. VAN DORST DCH, Mirabito Colafella KM, van Veghel R, Garrelds IM, et al
    Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment.
    Eur J Pharmacol. 2023 Nov 27:176199. doi: 10.1016/j.ejphar.2023.176199.
    PubMed     Abstract available
    
    
    
49. HO CY, Sun GC, Lin YT, Wong TY, et al
    Microglial activation and toll-like receptor 4-Dependent regulation of angiotensin II type I receptor-mu-opioid receptor 1 heterodimerization and hypertension in fructose-fed rats.
    Eur J Pharmacol. 2023 Nov 21:176171. doi: 10.1016/j.ejphar.2023.176171.
    PubMed     Abstract available
    
    
    
50. MATSUMOTO T, Taguchi K, Kobayashi T
    Role of TRPV4 on vascular tone regulation in pathophysiological states.
    Eur J Pharmacol. 2023;959:176104.
    PubMed     Abstract available
    
    
    
51. EDOSUYI O, Igbe I, Oyekan A
    Fumarate and its downstream signalling pathways in the cardiorenal system: Recent insights and novel expositions in the etiology of hypertension.
    Eur J Pharmacol. 2023 Nov 7:176186. doi: 10.1016/j.ejphar.2023.176186.
    PubMed     Abstract available
    
    
    
52. YI Y, Tianxin Y, Zhangchi L, Cui Z, et al
    Pinocembrin attenuates susceptibility to atrial fibrillation in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2023;960:176169.
    PubMed     Abstract available
    
    
    October 2023
53. KONG S, Yu J, Li HF, Xie YL, et al
    A ring N(CH(3))(2)-based derivative of resveratrol inhibits pulmonary vascular remodeling in hypoxia pulmonary hypertension.
    Eur J Pharmacol. 2023 Oct 9:176077. doi: 10.1016/j.ejphar.2023.176077.
    PubMed     Abstract available
    
    
    September 2023
54. NOAH AA, El-Mezayen NS, El-Ganainy SO, Darwish IE, et al
    Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl(4)-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-beta and gal-1/NRP-1/VEGFR2 pathways.
    Eur J Pharmacol. 2023 Sep 26:176066. doi: 10.1016/j.ejphar.2023.176066.
    PubMed     Abstract available
    
    
    
55. VALOVIC P, Behuliak M, Vaneckova I, Zicha J, et al
    Impaired vascular beta-adrenergic relaxation in spontaneously hypertensive rats: The differences between conduit and resistance arteries.
    Eur J Pharmacol. 2023 Sep 12:176045. doi: 10.1016/j.ejphar.2023.176045.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.